A Phase 2 interventional study of iloperidone and Risperidone in Schizophrenia, Iloperidone and Efficacy, sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2013-11-19.
Sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd. (part of Hansoh Pharmaceutical Group Company Limited) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing iloperidone in Schizophrenia — 2 open to participants now, 2 under way, 1 of them phase 3. iloperidone · Schizophrenia.
Among the 11 studies testing iloperidone in Schizophrenia, this one is the 6th largest by enrollment, is one of 2 that started in 2012, is the only one in phase 2, and was the 5th registered.
3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.
Browse Schizophrenia studies →2 of the 11 studies testing iloperidone in Schizophrenia are open now, in 1 country. Recruiting first, the newest first:
Vanda Pharmaceuticals · Sites in United States
Ages 18–65
Vanda Pharmaceuticals · Sites in United States
Ages 12–17
By country, each count listing its studies:
iloperidone: first FDA approval 2009 (FANAPT). What it is approved for, and how studies give it, is on its page →
Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2012.
This study's enrollment of 260 is above the median of 71 across 2,947 interventional studies indexed under Schizophrenia.
Median enrollment 260 across the 11 interventional studies. Of the 8 that completed or were terminated, 4 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 11 have an industry lead sponsor. The 5 most frequent:
This study is registered under Jiangsu Hansoh Pharmaceutical Co., Ltd., one of the names counted as Hansoh Pharmaceutical Group Company Limited. Under that name alone:
Jiangsu Hansoh Pharmaceutical Co., Ltd. is the lead sponsor of 138 studies on the registry; 72 are open to participants now.
Hansoh Pharmaceutical Group Company Limited has 7 studies filed under Schizophrenia — fewer than ten, so there is no comparison to draw.
1 of the studies testing iloperidone in Schizophrenia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06961968Phase 3Vanda PharmaceuticalsRandomized Withdrawal Study in Patients With Schizophrenia | 2027-11 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies testing iloperidone in Schizophrenia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether iloperidone is effective in the treatment of Schizophrenia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Risperidone
Drug: iloperidone
Iloperidone is being development as a treatment of schizophrenia. This trial will verify the safety and efficacy of iloperidone in patients with schizophrenia.
Risperidone is used for the treatment of schizophrenia.Risperidone is unique among most other atypicals in that it has high affinity for the D2 receptor whereas most other atypicals have 'loose binding' of the D2 receptor. It has actions at several 5-HT (serotonin) receptor subtypes.
Positive and Negative Symptom Scale(PANSS)-Total Score
Time frame: 6 weeks
Effective percentage(PANSS score reduce rate≥50%)
Time frame: 6 weeks
Change in scores from baseline to end point assessment on the PANSS Positive subscale (PANSS-P)
Time frame: 6 weeks
Change in scores from baseline to end point assessment on the PANSS Negative subscale (PANSS-N)
Time frame: 6 weeks
Change in scores from baseline to end point assessment on the PANSS General Psychopathology subscale(PANSS-GP)
Time frame: 6 weeks
The record gives a start of Jun 2012, a primary completion of Oct 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Iloperidone
Jiangsu Hansoh Pharmaceutical Co., Ltd. →